Trial
NCT03891979
Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma
Phase IVWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
NYU Langone Health
Collaborators
—
Condition
Pancreatic Cancer
Intervention
Pembrolizumab
Why stopped
Suspended due to Primary Investigator's decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-26